GSMS: Ranitidine Capsules 300 mg, Rx only, 100 count bottles (NDC 51407-098-01) Manufactured by N...

FDA Drug Recall #D-0308-2020 — Class II — November 6, 2019

Recall Summary

Recall Number D-0308-2020
Classification Class II — Moderate risk
Date Initiated November 6, 2019
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Golden State Medical Supply Inc.
Location Camarillo, CA
Product Type Drugs
Quantity N/A

Product Description

GSMS: Ranitidine Capsules 300 mg, Rx only, 100 count bottles (NDC 51407-098-01) Manufactured by Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520; Packaged by GSMS, Incorporated, Carmillo, CA 93012 USA.

Reason for Recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution Pattern

AZ, IA, MA, MO

Lot / Code Information

Lot Codes: GS023971, Exp. 10/31/2020; GS025527, Exp. 10/31/2020; GS025526, Exp. 10/31/2020; GS026114, Exp. 10/31/2020; GS025813, Exp. 10/31/2020; GS026189, Exp. 10/31/2021; GS027555, Exp. 7/31/2021; GS026190, Exp. 5/31/2021; GS026220, Exp. 05/31/2021; GS026584, Exp. 05/31/2021; GS027139, Exp. 05/31/2021; GS027554, Exp. 05/31/2021.

Other Recalls from Golden State Medical Supply Inc.

Recall # Classification Product Date
D-0235-2026 Class II Baclofen Tablets USP, 10 mg, 1000-count bottles... Nov 26, 2025
D-0158-2026 Class II NIACIN Extended-Release Tablets, USP, 1,000 mg,... Oct 20, 2025
D-0287-2025 Class II PRASUGREL TABLETS, 5 mg, 30 tablet bottles, Rx ... Mar 5, 2025
D-0568-2024 Class II Duloxetine Delayed-Release Capsules, USP, 30mg,... May 13, 2024
D-0349-2024 Class II Fluticasone Propionate Nasal Spray USP, 50 mcg ... Feb 14, 2024

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.